Latest News and Press Releases

Marvel Biosciences to participate in 2nd Neuroscience Innovation Partnering & Licensing Summit, allowing Marvel to showcase its progress on global stage

Marvel Biosciences Corp. announces it has identified two lead pediatric-friendly liquid formulations of its patented lead compound, MB-204.

Marvel announces financial and strategic backing from 5 Horizons Ventures to support its upcoming Phase 1 clinical trial of patented lead asset MB-204

Dosing of the first patient in the Phase 1 clinical trial of ADCX-020.

Marvel Biosciences secures $600,000 in non-dilutive funding from Alberta Innovates to support Phase I clinical trials of its autism-focused patented MB-204

Marvel Biosciences Selects Novotech as CRO for Its Phase I Clinical Trial of MB-204, lead asset discovery, a patented neuroactive adenosine A2A antagonist

The Lancet Microbe publishes SNIPR001 Phase 1: safe, gut‑restricted, microbiome stable; Phase 1b HSCT trial >50% enrolled.

Synklino, publishes data in the American Journal of Transplantation and will present this as a poster at the Cutting Edge of Transplantation (CEoT) Summit.

PHILADELPHIA, Pennsylvania and COPENHAGEN, Denmark, Jan. 23, 2026 (GLOBE NEWSWIRE) -- Alveus Therapeutics, Inc. (“Alveus”), a clinical-stage biotechnology company developing next-generation...

Agomab today announced positive interim results of the Phase 1 study of AGMB-447 in healthy participants.